• Maia Biotechnology posted a net loss of USD 6.37 million, widening 41% year over year.
• Operating loss widened to USD 6.95 million as total operating costs and expenses climbed 28% to USD 6.95 million.
• Research and development expense rose 10% to USD 3.53 million, while general and administrative expense increased 54% to USD 3.42 million.
• Net cash used in operating activities increased to USD 5.31 million, while net cash provided by financing activities jumped to USD 31.05 million following USD 33 million in gross proceeds from March equity offerings.
• Recent updates included more than two-year overall survival for eight patients in Phase 2 THIO-101 NSCLC data, activation of the first U.S. clinical site for the THIO-101 expansion trial, and a statement that net proceeds from the March offering are expected to fully fund the ongoing pivotal Phase 3 trial of ateganosine in NSCLC.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-022154), on May 11, 2026, and is solely responsible for the information contained therein.